ArcherDX's $55M infusion bolsters Stratafide broad companion test

LabPulse.com staff writers
Dec 16, 2019
2019 06 25 22 42 3358 Graph Arrow Up2 400

Molecular diagnostics company ArcherDX has closed a $55 million series C financing round and plans to use the cash to get its Stratafide companion diagnostic test for use across solid tumor types through registration and commercial launch.

According to Boulder, CO-based ArcherDX, the Stratafide test identifies actionable genomic alterations in tissue or blood samples; analysis may be done at any local lab with a sequencer. The test has received the breakthrough device designation from the U.S. Food and Drug Administration.

The series C financing round was led by Perceptive Advisors with existing investors, including Sands Capital, as well as new investors, including the Redmile Group. In addition to getting Stratafide through clearance and launch, the new funding will be used to help develop ArcherDX's personalized cancer monitoring platform, which will monitor patients for minimal residual disease to ensure therapies are working.

Latest in 510(k)
Fda Button Social
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
June 6, 2023
Digital Pathology Cytology Social
Leica Biosystems granted FDA clearance for Class II mismatch repair panel
April 3, 2023
Fda Button Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
March 20, 2023
Bd Vaginal Panel Cor System
Becton Dickinson nabs FDA clearance for infectious vaginitis molecular test
March 16, 2023
Related Stories
2019 04 17 00 53 3368 Dna Sequence 400
Molecular Diagnostics
Invitae, ArcherDX to merge
2020 01 03 00 14 8701 Illumina 400
Agreement
ArcherDX, Illumina expand cancer test partnership
2019 04 24 18 42 4242 Dna Blue 400
Hematologic Malignancies
ArcherDX partners with Illumina on companion tests
2019 11 06 19 11 2133 Promega Msi 20191106195132
510(k)
Promega, Merck team up on Keytruda companion test
More in 510(k)
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
The device has conducted more than 180 thousand assessments in pharmacies and primary care clinics in Europe; DeepX is poised to enter the U.S. market.
June 6, 2023
Fda Button Social
Leica Biosystems granted FDA clearance for Class II mismatch repair panel
The Bond MMR Antibody Panel is available for clinical use on its automated Bond-III and Bond-Max immunohistochemistry instruments.
April 3, 2023
Digital Pathology Cytology Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Becton Dickinson nabs FDA clearance for infectious vaginitis molecular test
The BD vaginal panel running on the high-throughput BD Cor molecular diagnostic system tests for multiple common types of vaginitis using only a swab and one test.
March 16, 2023
Bd Vaginal Panel Cor System
FDA grants clearance to Abbott for first commercial laboratory test to detect traumatic brain injury
The test runs on Abbott's Alinity i laboratory immunoassay instrument, providing a result in 18 minutes to help clinicians quickly assess concussion and triage patients, Abbott said. Negative results rule out the need for a CT scan.
March 7, 2023
Football Player Concussion Social
Copan Diagnostics receives second FDA clearance for semiautomated preanalytical processor
With this second clearance, Colibri can prepare microbial suspensions for antibiotic susceptibility testing with the BioMérieux Vitek 2 system.
October 11, 2022
Lab Virus Bacteria Research
OIG: FDA recommendations for future pandemics
OIG offered numerous recommendations to manage such infectious disease emergencies, saying the FDA should access and, when appropriate, revise its guidance for Emergency Use Authorization (EUA) submissions for tests.
September 21, 2022
2021 11 29 23 50 3003 Fda Button 20211129235739
Week in Review: Multicancer early detection at ESMO, DiaSorin nabs FDA clearance for COVID-19 kit, IVD industry urges Congress to enact SALSA, and more
Dear LabPulse.com member,
September 14, 2022
FDA grants 510(k) clearance to DiaSorin for COVID-19 kit
The kit, which runs on DiaSorin's Liaison MDX molecular diagnostics system, provides a sample-to-answer test for the detection of SARS-CoV-2 directly from nasopharyngeal or nasal swab specimens.
September 13, 2022
2021 08 23 18 25 2180 Covid Treatment Doctor 400
PixCell Medical, Insight Medical to distribute hematology analyzer
PixCell said that its HemoScreen hematology analyzer delivers lab-grade diagnostics at the point of care without the need for external reagents or extensive training.
September 5, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Cue Health requests FDA de novo clearance for at-home flu test
Clearance would permit the test to be used at home and elsewhere at the point-of-care (POC).
September 1, 2022
2022 09 02 19 52 9683 Flu Season Ahead 400
NanoDx, SkyWater launch nano biosensor
The companies said that as a result of the development, NanoDx is ready to prepare and submit the product for review by the U.S. Food and Drug Administration (FDA) with the aim of eventually commercializing a product based on the technology.
August 25, 2022
2021 06 30 22 19 4138 Digital Science Lab 400
Page 1 of 16
Next Page